Synergistic activity of the tyrocidines, antimicrobial cyclodecapeptides from Bacillus aneurinolyticus, with amphotericin B and caspofungin against Candida albicans biofilms

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3697-3707

  Troskie, Anscha Mari ^a   Rautenbach, Marina ^a   Delattin, Nicolas ^b   Vosloo, Johan Arnold ^a   Dathe, Margitta ^c   Cammue, Bruno P A ^b,d   Thevissen, Karin ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c LEIBNIZ INSTITUT FÜR MOLEKULARE PHARMAKOLOGIE   (Germany)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; ERGOSTEROL; GRAMICIDIN S; PHOSPHATIDYLCHOLINE; PROPIDIUM IODIDE; TYROCIDINE; ANTIFUNGAL AGENT; ECHINOCANDIN; PEPTIDE; REACTIVE OXYGEN METABOLITE;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACILLUS; BACILLUS ANEURINOLYTICUS; BIOFILM; CAENORHABDITIS ELEGANS; CANDIDA ALBICANS; CELL MATURATION; CELL MEMBRANE PERMEABILITY; CONTROLLED STUDY; DRUG POTENTIATION; FUNGAL MEMBRANE; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; ANIMAL; CANDIDIASIS; CHEMISTRY; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BACILLUS; BIOFILMS; CAENORHABDITIS ELEGANS; CANDIDA ALBICANS; CANDIDIASIS; CELL MEMBRANE PERMEABILITY; DRUG SYNERGISM; ECHINOCANDINS; MICROBIAL SENSITIVITY TESTS; PEPTIDES; REACTIVE OXYGEN SPECIES; TYROCIDINE;

EID: 84903209042     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02381-14     Document Type: Article

References (60)

1. Letscher-Bru V, Herbrecht R. 2003. Caspofungin: the first representative of a new antifungal class. J. Antimicrob. Chemother. 51:513-521. http://dx.doi.org/10.1093/jac/dkg117. (Pubitemid 36336143)
2. Beck-Sagué C, Jarvis WR. 1993. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System. J. Infect. Dis. 167:1247-1251. (Pubitemid 23115628)
3. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. 1996. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J. Infect. 33:23-32. http://dx.doi.org/10.1016/S0163- 4453(96)92700-0. (Pubitemid 26289847)
4. Ramage G, Bachmann S, Patterson TF, Wickes BL, López-Ribot JL. 2002. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J. Antimicrob. Chemother. 49:973-980. http://dx.doi.org/10.1093/jac/dkf049. (Pubitemid 34692891)
5. Ramage G, Mowat E, Jones B, Williams C, Lopez-Ribot J. 2009. Our current understanding of fungal biofilms. Crit. Rev. Microbiol. 35:340-355. http://dx.doi.org/10.3109/10408410903241436.
6. Tobudic S, Lassnigg A, Kratzer C, Graninger W, Presterl E. 2010. Antifungal activity of amphotericin B, caspofungin and posaconazole on Candida albicans biofilms in intermediate and mature development phases. Mycoses 53:208-214. http://dx.doi.org/10.1111/j.1439-0507.2009.01690.x.
7. Bink A, Vandenbosch D, Coenye T, Nelis H, Cammue BPA, Thevissen K. 2011. Superoxide dismutases are involved in Candida albicans biofilm persistence against miconazole. Antimicrob. Agents Chemother. 55:4033-4037. http://dx.doi.org/10.1128/AAC.00280-11.
8. Ferreira JAG, Carr JH, Starling CEF, de Resende MA, Donlan RM. 2009. Biofilm formation and effect of caspofungin on biofilm structure of Candida species bloodstream isolates. Antimicrob. Agents Chemother. 53:4377-4384. http://dx.doi.org/10.1128/AAC.00316-09.
9. Bink A, Pellens K, Cammue BPA, Thevissen K. 2011. Anti-biofilm strategies: how to eradicate Candida biofilms? Open Mycol. J. 5:29-38. http://dx.doi.org/10.2174/1874437001105010029.
10. Harriott MM, Lilly EA, Rodriguez TE, Fidel PL, Jr, Noverr MC. 2010. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 156:3635-3644. http://dx.doi.org/10.1099/mic.0.039354-0.
11. Blankenship JR, Mitchell AP. 2006. How to build a biofilm: a fungal perspective. Curr. Opin. Microbiol. 9:588-594. http://dx.doi.org/10.1016/j.mib. 2006.10.003. (Pubitemid 44791986)
12. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183:5385-5394. http://dx.doi.org/10.1128/JB.183.18.5385-5394.2001. (Pubitemid 32802612)
13. Crump JA, Collignon PJ. 2000. Intravascular catheter-associated infections. Eur. J. Clin. Microbiol. Infect. Dis. 19:1-8. http://dx.doi.org/10. 1007/s100960050001. (Pubitemid 30093374)
14. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, López-Ribot JL. 2002. In vitro activity of caspofungin against Candida albicans biofilms. Antimicrob. Agents Chemother. 46:3591-3596. http://dx.doi.org/10.1128/AAC.46.11.3591-3596.2002. (Pubitemid 35192931)
15. Hawser SP, Douglas LJ. 1995. Resistance of Candida albicans biofilms to antifungal agents in vitro. Antimicrob. Agents Chemother. 39:2128-2131. http://dx.doi.org/10.1128/AAC.39.9.2128.
16. Baillie GS, Douglas LJ. 1999. Candida biofilms and their susceptibility to antifungal agents. Methods Enzymol. 310:644-656. http://dx.doi.org/10.1016/ S0076-6879(99)10050-8. (Pubitemid 29504312)
17. Ramage G, Wickes BL, Lopez-Ribot JL. 2001. Biofilms of Candida albicans and their associated resistance to antifungal agents. Am. Clin. Lab. 20:42-44.
18. Laniado-Laborín R, Cabrales-Vargas MN. 2009. Amphotericin B: side effects and toxicity. Rev. Iberoam. Micol. 26:223-227. http://dx.doi.org/10. 1016/j.riam.2009.06.003.
19. DiDone L, Oga D, Krysan DJ. 2011. A novel assay of biofilm antifungal activity reveals that amphotericin B and caspofungin lyse Candida albicans cells in biofilms. Yeast 28:561-568. http://dx.doi.org/10.1002/yea.1860.
20. Brajtburg J, Bolard J. 1996. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev. 9:512-531. (Pubitemid 26366536)
21. Johnson RH, Einstein HE. 2007. Amphotericin B and coccidioidomycosis. Ann. N. Y. Acad. Sci. 1111:434-441. http://dx.doi.org/10.1196/annals.1406.019. (Pubitemid 47573021)
22. Conly J, Rennie R, Johnson J, Farah S, Hellman L. 1992. Disseminated candidiasis due to amphotericin B-resistant Candida albicans. J. Infect. Dis. 165:761-764. http://dx.doi.org/10.1093/infdis/165.4.761.
23. Kelly SL, Lamb DC, Kelly DE, Manning NJ, Loeffler J, Hebart H, Schumacher U, Einsele H. 1997. Resistance to fluconazole and cross-resistance to amphotericin B in Candida albicans from AIDS patients caused by defective sterol Δ5,6-desaturation. FEBS Lett. 400:80-82. http://dx.doi.org/10.1016/S0014- 5793(96)01360-9. (Pubitemid 27046825)
24. Nolte FS, Parkinson T, Falconer DJ, Dix S, Williams J, Gilmore C, Geller R, Wingard JR. 1997. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia. Antimicrob. Agents Chemother. 44:196-199. (Pubitemid 26428157)
25. Deresinski SC, Stevens DA. 2003. Caspofungin. Clin. Infect. Dis. 36: 1445-1457. http://dx.doi.org/10.1086/375080. (Pubitemid 36702880)
26. Hancock RE, Scott MG. 2000. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. U. S. A. 97:8856-8861. http://dx.doi.org/10. 1073/pnas.97.16.8856. (Pubitemid 30626637)
27. Hancock RE, Diamond G. 2000. The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. 8:402-410. http://dx.doi.org/10.1016/ S0966-842X(00)01823-0.
28. Hotchkiss RD, Dubos RJ. 1941. The isolation of bactericidal substances from cultures of Bacillus brevis. J. Biol. Chem. 141:155-162.
29. Tang XJ, Thibault P, Boyd RK. 1992. Characterisation of the tyrocidine and gramicidin fractions of the tyrothricin complex from Bacillus brevis using liquid chromatography and mass spectrometry. Int. J. Mass Spectrom. Ion Processes 122:153-179. http://dx.doi.org/10.1016/0168-1176(92)87015-7.
30. Rankin LM. 1944. The use of tyrothricin in the treatment of ulcers of the skin. Am. J. Surg. 65:391-392. http://dx.doi.org/10.1016/S0002-9610(44)90351-X.
31. Spathelf BM, Rautenbach M. 2009. Anti-listerial activity and structure-activity relationships of the six major tyrocidines, cyclic decapeptides from Bacillus aneurinolyticus. Bioorg. Med. Chem. 17:5541-5548. http://dx.doi.org/10.1016/j.bmc.2009.06.029.
32. Rautenbach M, Vlok NM, Stander M, Hoppe HC. 2007. Inhibition of malaria parasite blood stages by tyrocidines, membrane-active cyclic peptide antibiotics from Bacillus brevis. Biochim. Biophys. Acta 1768:1488-1497. http://dx.doi.org/10.1016/j.bbamem.2007.01.015. (Pubitemid 46782696)
33. Kretschmar M, Nichterlein T, Nebe CT, Hof H, Burger KJ. 1996. Fungicidal effect of tyrothricin on Candida albicans. Mycoses 39:45-50. http://dx.doi.org/10.1111/j.1439-0507.1996.tb00083.x. (Pubitemid 26163854)
34. Vosloo JA, Stander M, Leussa AN-N, Spathelf BM, Rautenbach M. 2013. Manipulation of the tyrothricin production profile of Bacillus aneurinolyticus. Microbiology 159:2200-2211. http://dx.doi.org/10.1099/mic.0.068734-0.
35. Spathelf BM. 2010. Qualitative structure-activity relationships of the major tyrocidines, cyclic decapeptides from Bacillus aneurinolyticus. Ph.D. thesis. Department of Biochemistry, University of Stellenbosch, Stellenbosch, South Africa. http://scholar.sun.ac.za/handle/10019.1/4001.
36. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 2nd ed. CLSI M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.
37. Delattin N, De Brucker K, Craik DJ, Cheneval O, Fröhlich M, Veber M, Girandon L, Davis TR, Weeks AE, Kumamoto CA, Cos P, Coenye T, De Coninck B, Cammue BPA, Thevissen K. 2014. The plant-derived decapeptide OSIP108 interferes with Candida albicans biofilm formation without affecting cell viability. Antimicrob. Agents Chemother. 58:2647-2656. http://dx.doi.org/10.1128/AAC.01274- 13.
38. Peeters E, Nelis HJ, Coenye T. 2007. Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. J. Microbiol. Methods 72:157-165. http://dx.doi.org/10.1016/j.mimet.2007.11.010.
39. Van den Driessche F, Rigole P, Brackman G, Coenye T. 2013. Optimization of resazurin-based viability staining for quantification of microbial biofilms. J. Microbiol. Methods 98:31-34. http://dx.doi.org/10.1016/j.mimet.2013.12.011.
40. Bink A, Kucharíková S, Neirinck B, Vleugels J, Van Dijck P, Cammue BP, Thevissen K. 2012. The nonsteroidal anti-inflammatory drug diclofenac potentiates the in vivo activity of caspofungin against Candida albicans biofilms. J. Infect. Dis. 206:1790-1797. http://dx.doi.org/10.1093/ infdis/jis594.
41. Dathe M, Schümann M, Wieprecht T, Winkler A, Beyermann M, Krause E, Matsuzaki K, Murase O, Bienert M. 1996. Peptide helicity and membrane surface charge modulate the balance of electrostatic and hydrophobic interactions with lipid bilayers and biological membranes. Biochemistry 35:12612-12622. http://dx.doi.org/10.1021/bi960835f. (Pubitemid 26318059)
42. Dathe M, Nikolenko H, Klose J, Bienert M. 2004. Cyclization increases the antimicrobial activity and selectivity of arginine- and tryptophan-containing hexapeptides. Biochemistry 43:9140-9150. http://dx.doi.org/10.1021/bi035948v. (Pubitemid 38924447)
43. Aerts AM, François IE, Meert EM, Li QT, Cammue BP, Thevissen K. 2007. The antifungal activity of RsAFP2, a plant defensin from Raphanus sativus, involves the induction of reactive oxygen species in Candida albicans. J. Mol. Microbiol. Biotechnol. 13:243-247. http://dx.doi.org/10.1159/000104753. (Pubitemid 47378154)
44. François IE, Thevissen K, Pellens K, Meert EM, Heeres J, Freyne E, Coesemans E, Viellevoye M, Deroose F, Martinez Gonzalez S, Pastor J, Corens D, Meerpoel L, Borgers M, Ausma J, Dispersyn GD, Cammue BP. 2009. Design and synthesis of a series of piperazine-1-carboxamidine derivatives with antifungal activity resulting from accumulation of endogenous reactive oxygen species. ChemMedChem 4:1714-1721. http://dx.doi.org/10.1002/cmdc.200900249.
45. Breger J, Fuchs BB, Aperis G, Moy TI, Ausubel FM, Mylonakis E. 2007. Antifungal chemical compounds identified using a C. elegans pathogenicity assay. PLoS Pathog. 3:e18. http://dx.doi.org/10.1371/journal.ppat.0030018.
46. Rautenbach M, Gerstner GD, Vlok NM, Kulenkampff J, Westerhoff HV. 2006. Analyses of dose-response curves to compare the antimicrobial activity of model cationic -helical peptides highlights the necessity for a minimum of two activity parameters. Anal. Biochem. 350:81-90. http://dx.doi.org/10.1016/j.ab. 2005.11.027. (Pubitemid 43247628)
47. Katsu T, Kobayashi H, Fujita Y. 1986. Mode of action of gramicidin S on Escherichia coli membrane. Biochim. Biophys. Acta 860:608-619. http://dx.doi.org/10.1016/0005-2736(86)90560-2. (Pubitemid 16027968)
48. Jelokhani-Niaraki M, Hodges RS, Meissner JE, Hassenstein UE, Wheaton L. 2008. Interaction of gramicidin S and its aromatic amino-acid analog with phospholipid membranes. Biophys. J. 95:3306-3321. http://dx.doi.org/10.1529/ biophysj.108.137471.
49. Aranda FJ, de Kruijff B. 1988. Interrelationships between tyrocidine and gramicidin A′ in their interaction with phospholipids in model membranes. Biochim. Biophys. Acta 937:195-203. http://dx.doi.org/10.1016/0005-2736(88) 90241-6. (Pubitemid 18018628)
50. Mann FC, Heilman D, Herrell WE. 1943. Effect of serum on hemolysis by gramicidin and tyrocidine. Exp. Med. Biol. 52:31-33. http://dx.doi.org/10.3181/ 00379727-52-14011.
51. Mach B, Slayman CW. 1966. Mode of action of tyrocidine on Neurospora. Biochim. Biophys. Acta 124:351-361. http://dx.doi.org/10.1016/0304-4165(66) 90198-X.
52. Troskie AM. 2014. Tyrocidines, cyclic decapeptides produced by soil bacilli, as potent inhibitors of fungal pathogens. Ph.D. thesis. Department of Biochemistry, University of Stellenbosch, Stellenbosch, South Africa.
53. Dubos RJ, Hotchkiss RD. 1941. The production of bactericidal substances by aerobic sporulating bacilli. J. Exp. Med. 73:629-640. http://dx.doi.org/10. 1084/jem.73.5.629.
54. Loll PJ, Upton EC, Nahoum V, Economou NJ, Cocklin S. 2014. The high resolution structure of tyrocidine A reveals an amphipathic dimer. Biochim. Biophys. Acta 1838:1199-1207. http://dx.doi.org/10.1016/j.bbamem.2014.01.033.
55. Braun P, von Heijne G. 1999. The aromatic residues Trp and Phe have different effects on the positioning of a transmembrane helix in the microsomal membrane. Biochemistry 38:9778-9782. http://dx.doi.org/10.1021/bi990923a.
56. Shai Y. 2002. Mode of action of membrane active antimicrobial peptides. Biopolymers 66:236-248. http://dx.doi.org/10.1002/bip.10260. (Pubitemid 36098316)
57. Munyuki G, Jackson GE, Venter GA, Kövér KE, Szilágyi L, Rautenbach M, Spathelf BM, Bhattacharya B, van der Spoel D. 2013. β-Sheet structures and dimer models of two major tyrocidines, antimicrobial peptides from Bacillus aneurinolyticus. Biochemistry 52:7798-7806. http://dx.doi.org/10.1021/bi401363m.
58. Frecer V. 2006. QSAR analysis of antimicrobial and haemolytic effects of cyclic cationic antimicrobial peptides derived from protegrin-1. Bioorg. Med. Chem. 14:6065-6074. http://dx.doi.org/10.1016/j.bmc.2006.05.005. (Pubitemid 44080572)
59. Dubos RJ, Cattaneo C. 1939. Studies on a bactericidal agent extracted from a soil bacillus. III. Preparation and activity of a protein-free fraction. J. Exp. Med. 70:249-256.
60. Taliaferro LC, Coulston F, Silverman M. 1944. The antimalarial activity of tyrothricin against Plasmodium gallinaceum. J. Infect. Dis. 75:179-212. http://dx.doi.org/10.1093/infdis/75.3.179.